retatrutide liver benefits Triple hormone receptor agonist for metabolic dysfunction-associated steatotic disease: a randomized phase 2a trial Retatrutide Subcutaneous Fat Loss Results:

Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial

Step three: combination and intensification For patients who do not reach their targets on either medication alone, combining basal insulin with a GLP-1 agonist is an increasingly popular strategy

In the same study, 9-20% of patients who used retatrutide experienced diarrhea

SmPCs for all approved weight management medicines are available on the Electronic Medicines Compendium (www.medicines.org.uk/emc)

The eligibility criteria of the Novo Nordisk Patient Assistant Program (PAP) in 2025: You must have a valid prescription from a certified healthcare professional for an FDA-approved indication

Diabetologia 55 , 24562468 (2012)